CTS Corporation (CTS) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This summary covers the unaudited quarterly report (Form 10-Q) for CTS Corporation for the period ended June 30, 2025. CTS is a global manufacturer of sensors, connectivity components, and actuators serving transportation, industrial, medical, and aerospace & defense markets. The company operates as a single reportable segment.
Key Financial Metrics
| Metric | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Net Sales | $135.3M | $130.2M | $261.1M | $255.9M |
| Gross Margin | $52.4M (38.7%) | $46.4M (35.6%) | $99.0M (37.9%) | $91.5M (35.7%) |
| Operating Earnings | $22.7M (16.8%) | $17.8M (13.6%) | $39.0M (14.9%) | $32.3M (12.6%) |
| Net Earnings | $18.5M | $14.7M | $31.9M | $25.8M |
| Diluted EPS | $0.62 | $0.48 | $1.06 | $0.84 |
| Cash from Operations (YTD) | $43.9M (vs $37.9M YTD 2024) | |||
| Long-Term Debt | $88.0M (Outstanding balance) | |||
| Cash & Equivalents | $99.4M (as of June 30, 2025) |
Material Changes vs. Prior Period
- Revenue Growth: Q2 2025 net sales increased 4.0% year-over-year. Growth was driven by the SyQwest acquisition (+$4.5M), medical market expansion, and industrial recovery. Transportation sales declined 5.5% due to lower commercial vehicle volumes and reduced sales in China.
- Margin Expansion: Gross margin percentage improved to 38.7% from 35.6%, attributed to favorable product mix, operational improvements, and a net foreign exchange benefit of approximately $1.0M.
- Expense Management: Restructuring charges decreased significantly to $0.3M in Q2 2025 from $1.2M in Q2 2024, primarily due to reduced headcount reduction costs. SG&A expenses rose slightly due to depreciation and amortization from the SyQwest acquisition.
- Accounting Corrections: The company corrected immaterial prior period errors related to the SyQwest acquisition and foreign currency impacts on debt. These corrections reduced previously reported 2024 net earnings by $2.6M and adjusted 2024 balance sheet items including inventory and goodwill.
Guidance, Outlook, and Risks
- Outlook: Management notes continued recovery in the industrial market and growth momentum in the medical sector. The company expects to maintain liquidity through operating cash flows and its $400M revolving credit facility.
- Capital Allocation: The company continues its share repurchase program, having purchased 411,650 shares in Q2 2025. Approximately $38.1M remains available under the current authorization. Quarterly dividends of $0.04 per share were declared.
- Risks & Contingencies:
- Tariffs & Trade: Significant changes to U.S. and global tariffs in 2025 create uncertainty regarding cost structures and pricing.
- Environmental: The company faces potential liability for environmental remediation at the Asheville, NC site, with an estimated exposure between $1.9M and $9.95M. A loss estimate of $1.9M is currently accrued.
- Legislation: The "One Big Beautiful Bill Act" (OBBBA) signed in July 2025 introduces tax law changes; the financial impact is currently being evaluated.
Investor Verification Checklist
- Verify the impact of the SyQwest acquisition integration on future organic growth rates versus acquisition-driven growth.
- Monitor the transportation market recovery, specifically regarding commercial vehicle volumes and China sales exposure.
- Review the status of the Asheville, NC environmental remediation and potential for costs to exceed the $1.9M accrual.
- Assess the financial impact of the newly enacted OBBBA tax legislation on future effective tax rates.
- Track the execution of the share repurchase program and the remaining $38.1M authorization.